94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Endocrinol.
Sec. Cellular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1569579
Inflammasomes: Novel therapeutic targets for Metabolic Syndrome?
Provisionally accepted- 1Changzhou No.2 People's Hospital, Changzhou, China
- 2Medical Research Center, Changzhou No.2 People's Hospital, Changzhou, Jiangsu Province, China
- 3School of Nursing, Jilin University, Changchun, Jilin Province, China
- 4Department of Pediatrics, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic inflammation is a hallmark for Metabolic Syndrome (MetS). It is also one of the most important risk factors for insulin resistance and metabolic disorders.Inflammasomes, which are intracellular multiprotein complexes within the innate immune system, regulate the production and maturation of pro-inflammatory cytokines including interleukin-1β (IL-1β) and IL-18 upon sensing pathogens or danger signals in the cytosol. A growing body of evidence indicates that inflammasomes play a pivotal role in the pathophysiology and progression of metabolic diseases, as deficiency in the key component of inflammasomes protects mice from high fat diet induced obesity and insulin resistance. Thus, in this review, we will summarize the role of inflammasomes in MetS and how to treat MetS by targeting inflammasomes. This may provide novel insights and therapeutic targets for treating metabolic disorders.
Keywords: Obesity, diabetes, Dyslipidemia, Inflammation, innate immunity, Interleukins
Received: 01 Feb 2025; Accepted: 18 Apr 2025.
Copyright: © 2025 Cao, Yang, Zhang, Wang and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Pengyu Cao, Changzhou No.2 People's Hospital, Changzhou, China
Zhenwei Gong, Department of Pediatrics, Children’s Hospital of Pittsburgh, Pittsburgh, PA 15224, Pennsylvania, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.